Literature DB >> 17020873

A case of acute promyelocytic leukemia during gefitinib treatment.

Daisuke Ennishi, Nobuo Sezaki, Tadasi Senoo, Yasuhito Terui, Kiyohiko Hatake, Norihiko Hino.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17020873     DOI： 10.1532/IJH97.06149

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  7 in total

1.  APL during gefitinib treatment for non-small-cell lung cancer.

Authors:  Akiko Uchida; Keitaro Matsuo; Mitsune Tanimoto
Journal:  N Engl J Med       Date:  2005-02-24       Impact factor: 91.245

2.  Diagnosis and monitoring of PML-RARA-positive acute promyelocytic leukemia by qualitative RT-PCR.

Authors:  Vincenzo Rossi; Laura Levati; Andrea Biondi
Journal:  Methods Mol Med       Date:  2006

3.  DNA topoisomerase II in therapy-related acute promyelocytic leukemia.

Authors:  Anita R Mistry; Carolyn A Felix; Ryan J Whitmarsh; Annabel Mason; Andreas Reiter; Bruno Cassinat; Anne Parry; Christoph Walz; Joseph L Wiemels; Mark R Segal; Lionel Adès; Ian A Blair; Neil Osheroff; Andrew J Peniket; Marina Lafage-Pochitaloff; Nicholas C P Cross; Christine Chomienne; Ellen Solomon; Pierre Fenaux; David Grimwade
Journal:  N Engl J Med       Date:  2005-04-14       Impact factor: 91.245

4.  Secondary leukaemia after cure for locally advanced NSCLC: alkylating type secondary leukaemia after induction therapy with docetaxel and carboplatin for NSCLC IIIB.

Authors:  Frank Griesinger; Michael Metz; Lorenz Trümper; Thomas Schulz; Detlef Haase
Journal:  Lung Cancer       Date:  2004-05       Impact factor: 5.705

5.  Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience.

Authors:  Alessandro Pulsoni; Livio Pagano; Francesco Lo Coco; Giuseppe Avvisati; Luca Mele; Eros Di Bona; Rosangela Invernizzi; Franco Leoni; Filippo Marmont; Alfonso Mele; Lorella Melillo; Anna Maria Nosari; Enrico Maria Pogliani; Marco Vignetti; Giuseppe Visani; Vittorina Zagonel; Giuseppe Leone; Franco Mandelli
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

6.  Therapy-related acute promyelocytic leukemia.

Authors:  M Beaumont; M Sanz; P M Carli; F Maloisel; X Thomas; L Detourmignies; A Guerci; N Gratecos; C Rayon; J San Miguel; J Odriozola; J Y Cahn; F Huguet; A Vekhof; A Stamatoulas; H Dombret; F Capote; J Esteve; A M Stoppa; P Fenaux
Journal:  J Clin Oncol       Date:  2003-06-01       Impact factor: 44.544

7.  Risk of leukemia after platinum-based chemotherapy for ovarian cancer.

Authors:  L B Travis; E J Holowaty; K Bergfeldt; C F Lynch; B A Kohler; T Wiklund; R E Curtis; P Hall; M Andersson; E Pukkala; J Sturgeon; M Stovall
Journal:  N Engl J Med       Date:  1999-02-04       Impact factor: 91.245
  7 in total
  2 in total

1.  Lapatinib induces autophagy, apoptosis and megakaryocytic differentiation in chronic myelogenous leukemia K562 cells.

Authors:  Huey-Lan Huang; Yu-Chieh Chen; Yu-Chuen Huang; Kai-Chien Yang; Hsin yi Pan; Shou-Ping Shih; Yu-Jen Chen
Journal:  PLoS One       Date:  2011-12-22       Impact factor: 3.240

2.  Lapatinib induces autophagic cell death and differentiation in acute myeloblastic leukemia.

Authors:  Yu-Jen Chen; Li-Wen Fang; Wen-Chi Su; Wen-Yi Hsu; Kai-Chien Yang; Huey-Lan Huang
Journal:  Onco Targets Ther       Date:  2016-07-20       Impact factor: 4.147
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.